Articles

The product is being voluntarily recalled because of powder leakage due to seal integrity issues.

InvaGen Pharmaceuticals Recalls Vigabatrin for Oral Solution, USP 500 mg

The agency released two guidance documents on the interim policy on compounding using bulk drug substances for both outsourcing and non-outsourcing facilities.

FDA Releases Compounding Guidance

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Pharmaceutical Technology Europe® spoke with Fiona Bellot, sales director, Cellexus BioreactorSystems, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

A Look at New Airlift Technology in Single-Use Bioreactors Systems

Feliza Mirasol is the science editor for 

AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).

AbbVie to Acquire ImmunoGen in Deal Valued at $10.1 Billion

This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.

AbbVie Collaborates with BigHat Biosciences on Next-Gen Therapeutic Antibodies

MilliporeSigma’s new platform combines generative AI, machine learning, and computer-aided drug-design aimed at increasing the success rate of new drugs and therapies.

MilliporeSigma Launches AI Solution for Integrating Drug Discovery and Molecule Synthesis

AstraZeneca will utilize Absci’s AI antibody drug creation platform to create an AI-designed antibody.  

Absci and AstraZeneca Collaborate on AI-Driven Oncology Candidate

The medicines, levetiracetam and clobazam, may a cause life-threatening reaction to patients if not caught and treated quickly. 

FDA Warns of Rare but Serious Drug Reaction to Antiseizure Medicines

Novartis has issued a nationwide voluntary recall of two lots of Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL because of crystallization issues.

Novartis Voluntarily Recalls Two Lots of Sandimmune Oral Solution, 100 mg/mL

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Drug shortages across Europe are being exacerbated by increased demand, struggling supply chains, and manufacturer suspensions.

News